Investigational drug · Phase 3
TVAV-008
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic hepatitisB.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TVAV-008"
First trial start
2025
Dec 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TVAV-008", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic hepatitisB
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TVAV-008" as an intervention, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis BPivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07282249 · 630 participants (planned) · Start Dec 31, 2025 · Primary completion Apr 30, 2027
Drug: TVAV-008; PegIFNα2b and 1 more · For: Chronic hepatitisB
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.Industry
NCT07897448 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; TVAX-008 and 2 more · For: Chronic Hepatitis B
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Ausper Biopharma Co., Ltd.Industry
NCT07876856 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; Placebo and 1 more · For: Chronic Hepatitis B
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.